2024/04/25 |
We have discovered stanniocalcin1 as cardiotoxic defence gene in 2015. the potential clinical applications of stanniocalcin in oncocardiology include its use as a biomarker for cancer therapy-induced cardiotoxicity, its potential as a therapeutic target for cardioprotection, and its role in regulating calcium homeostasis, which may be relevant for managing calcium-related cardiovascular complications in cancer patients.